Baseline monocytes ≥ 925/μL appear to represent a rare outlier phenotype rather than a generalizable predictor of adalimumab response in hidradenitis suppurativa
- 20 February 2026
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , e453-e454
Abstract
No abstract availableKeywords
Funding Information
- LEO Fondet
- Novo Nordisk Fonden
This publication has 4 references indexed in Scilit:
- Adalimumab for the treatment of hidradenitis suppurativa: evaluation of clinical response and impact on inflammatory markersEuropean Journal Of Dermatology, 2025
- Circulating monocytes as a marker of response to adalimumab in patients with hidradenitis suppurativa: A single institution, real-world cohort studyJournal of the American Academy of Dermatology, 2024
- Assessment of metabolic dysfunction‐associated steatotic liver disease in patients with hidradenitis suppurativa: A cross‐sectional studyJournal of the European Academy of Dermatology and Venereology, 2024
- BIOSKIN: A Protocol for the Copenhagen Translational Skin Immunology Biobank and Research ProgrammeBMJ Open, 2024